Drug Profile
Montelukast - Merck & Co
Alternative Names: KIPRES; L-706631; MK-0476; MK-476; Montegen; Montelukast sodium; Romilast; SingulairLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Merck & Co
- Developer Banyu; CHA University; Kyorin Pharmaceutical; Merck & Co; Merck Sharp & Dohme; Sun Pharmaceutical Industries
- Class Acetates; Anti-inflammatories; Antiasthmatics; Antidementias; Bronchodilators; Neuroprotectants; Nootropics; Quinolines; Small molecules
- Mechanism of Action Leukotriene D4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Allergic rhinitis; Asthma; Exercise-induced asthma; Perennial allergic rhinitis; Seasonal allergic rhinitis
- No development reported Bronchitis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Allergic-rhinitis(In children) in South Korea (PO, Tablet)
- 11 Dec 2015 Launched for Allergic rhinitis in Japan (KIPRES® OD tablets 10mg)
- 11 Dec 2015 Launched for Asthma in Japan (KIPRES® OD tablets 10mg)